News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Clara Lam

Articles by Clara Lam

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

ByClara Lam,Zakiya Haji-Noor,Simon Collin,Lisa Okazaki,Simone T. Sredni,Miriam Haviland,Angel Valladares,Caroline Tai,Joseph Imperato

May 31st 2025

41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists

ByClara Lam,Zakiya Haji-Noor,Simon Collin,Lisa Okazaki,Simone T. Sredni,Miriam Haviland,Joseph Imperato,Caroline Tai,Angel Valladares

May 30th 2025

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

ByChia Jie Tan,Connor Willis,Trang Au,Matthew Schabath, PhD,Chenghui Li,Kristen Kelley,Xiaoqing Xu,Leah Park,Clara Lam,Sandhya Mehta,Jackie Kwong,Diana Brixner,David Stenehjem

April 17th 2025

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

BySandhya Mehta,Kristin M. Zimmerman Savill,Peng Wang,Prathamesh Pathak,Clara Lam,Jackie Kwong,Bruce Feinberg

July 28th 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC